Tag Archives: Thomas Lönngren

Regulator Move Re-Opens Arguments over European Transparency

By Julian Upton | Published: March 9, 2011
At the end of last month, European public health and transparency campaigners sent a letter to EC health commissioner John Dalli, outlining their concerns about former EMA head Thomas Lönngren’s recent career move. The Alliance for Lobbying Transparency and Ethics Regulation (ALTER-EU), Health Action International (HAI) Europe, the International Society of Drug Bulletins (ISDB) — and [...]
Posted in Europe, Global, Regulatory | Also tagged , , , , | Leave a comment

Former EMA Head Back in the Regulatory Saddle

By Julian Upton | Published: January 17, 2011
His decade-long tenure as head of the European Medicines Agency (EMA) may have ended, but Thomas Lönngren is already back in the regulatory saddle as a strategic advisor to NDA Group, an independent consulting group focused on reducing wasted drug development costs, ensuring new medicines get to market faster, and “improving the performance of the [...]
Posted in Europe, Global, Market Access, People, R&D, Regulatory, leadership, pricing | Also tagged , , , | Leave a comment

Exclusive Interview: The European Medicine Agency's Thomas Lönngren

By William Looney | Published: December 14, 2010
The European Medicines Agency (EMA) is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. In return, EMA has made a virtue of necessity. It filled the regulatory [...]
Posted in Europe, Global, People, Regulatory, leadership | Also tagged , , , | 2 Comments